TriSalus Life Sciences, Inc.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(unaudited, in thousands except share and per share data)
| March 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $13,000 | $8,525 |
| Accounts receivable, net | 5,453 | 5,087 |
| Inventory, net | 4,162 | 4,048 |
| Prepaid expenses | 2,481 | 3,009 |
| Total current assets | 25,096 | 20,669 |
| Property and equipment, net | 1,968 | 1,669 |
| Right-of-use assets | 1,137 | 1,210 |
| Other assets | 424 | 423 |
| Total assets | $28,625 | $23,971 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Trade payables | $2,806 | $2,274 |
| Accrued liabilities | 8,403 | 7,355 |
| Short-term lease liabilities | 118 | 216 |
| Other current liabilities | 426 | 383 |
| Total current liabilities | 11,753 | 10,228 |
| Long-term debt, net of unamortized discount and debt issuance costs | 31,699 | 22,084 |
| Revenue base redemption liability | 564 | 507 |
| Long-term lease liabilities | 1,299 | 1,329 |
| Contingent earnout liability | 8,221 | 7,401 |
| Warrant and SEPA liabilities | 9,459 | 8,316 |
| Total liabilities | 62,995 | 49,865 |
| Commitments and contingencies | ||
| Stockholders’ deficit: | ||
| Preferred Stock, Convertible Series A, $0.0001 par value per share, $10.00 liquidation value per share. Authorized 10,000,000 shares at March 31, 2025 and December 31, 2024, respectively; issued and outstanding, 3,620,002 and 3,985,002 shares at March 31, 2025, and December 31, 2024, respectively. | — | — |
| Common stock, $0.0001 par value per share. Authorized 400,000,000 shares at March 31, 2025 and December 31, 2024, respectively; issued and outstanding, 32,272,462 and 31,279,264 shares at March 31, 2025, and December 31, 2024, respectively. | 3 | 3 |
| Additional paid-in capital | 255,551 | 253,652 |
| Accumulated deficit | (289,924) | (279,549) |
| Total stockholders’ deficit | (34,370) | (25,894) |
| Total liabilities and stockholders’ deficit | $28,625 | $23,971 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.